CPSE:GMABBiotechs
Genmab (CPSE:GMAB) Valuation Update Following New Epcoritamab Lymphoma Data from ASH 2025
Genmab (CPSE:GMAB) just put epcoritamab back in the spotlight by unveiling fresh ASH 2025 data across multiple lymphoma trials that sharpen the drug’s profile and give investors more to consider.
See our latest analysis for Genmab.
Those ASH readouts land at a time when momentum in Genmab’s shares is clearly building, with a roughly 32% year to date share price return and a 36% one year total shareholder return, in contrast with still negative three year total shareholder returns.
If...